Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Philogen SpA ( (IT:PHIL) ) has issued an update.
Philogen S.p.A. has announced the total amount of voting rights ahead of its upcoming Shareholders’ Meeting. The company disclosed that its share capital consists of 40,611,111 shares, translating to 63,347,611 voting rights. This announcement underscores Philogen’s commitment to transparency and provides stakeholders with crucial information about its governance structure, potentially impacting investor confidence and market perception.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company focusing on the research and development of pharmaceutical products for high-mortality diseases. The company specializes in creating targeted anti-cancer drugs using high-affinity ligands for tumor markers. Philogen’s innovative approach, known as tumor targeting, aims to deliver potent therapeutic agents directly to tumors while sparing healthy tissues. The company leverages proprietary technologies, extensive development experience, and a robust portfolio of patents to generate and commercialize treatments for diseases lacking satisfactory therapies.
YTD Price Performance: 7.89%
Average Trading Volume: 212
Technical Sentiment Signal: Strong Sell
Current Market Cap: €584.9M
For a thorough assessment of PHIL stock, go to TipRanks’ Stock Analysis page.